Drug intelligence / Profile preview

KL002

Development stage: Unknown
Lead developer: Kanglin Biotechnology
Modality: Small Molecules
Administration: Intraputaminal

Overview

KL002 is a bioactive small molecule with the chemical formula C22H21IN2O3S and a molecular weight of 520.38. It is categorized under bioactive small molecules and has been studied in the context of the ubiquitin/proteasome system, as well as Huntington's disease research[4]. KL002 has also been investigated for its potential use in treating advanced primary Parkinson's disease, where it was administered via bilateral intraputaminal injections in an open-label dose-escalation clinical study[5]. The mechanism of action and specific molecular targets for KL002 are not explicitly detailed in available sources.

Beyond the preview

Go deeper on KL002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KL002.

Explore the full profile